Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUPRENZA vs ETHRANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
Induction and maintenance of general anesthesia
Adults: 200 mg orally twice daily with meals.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Primarily hepatic via cytochrome P450 (CYP2E1); minor metabolism to fluoride ions.
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Approximately 95-98% bound to plasma proteins, primarily albumin.
Approximately 30-40%, primarily to albumin.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Vd: 1.2-2.0 L/kg, indicating extensive distribution into tissues, especially fat.
Oral bioavailability is approximately 70-80%.
By inhalation: 100% as delivered; not administered orally.
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
No dose adjustment required for GFR >10 m L/min; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation of inorganic fluoride metabolites.
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment as metabolism may be decreased.
Not recommended for patients under 18 years; safety and efficacy not established.
Induction: 2-5% inspired concentration; Maintenance: 1-3% inspired concentration, adjusted to age and response.
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
Lower inspired concentrations (0.5-2%) recommended due to increased sensitivity and reduced clearance; titrate to effect.
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
None
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
May cause dose-dependent cardiovascular depression,Risk of malignant hyperthermia,Potential for nephrotoxicity due to fluoride release,Hepatotoxicity risk, especially with repeated use,Neurologic effects including seizure activity at high doses
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected susceptibility to malignant hyperthermia,Severe hepatic impairment,Uncontrolled epilepsy
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
No specific food interactions. Patient must follow preoperative fasting guidelines (nil per os, NPO) as directed by anesthesiologist to reduce risk of aspiration.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal hypoxia from maternal hypotension.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
Excreted in breast milk in low amounts; M/P ratio not established. Consider benefits of breastfeeding vs. risk of infant exposure. Minimal systemic absorption in infant expected.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
No specific dose adjustments required for pregnancy; however, MAC decreases by approximately 30% during pregnancy due to hormonal changes and increased progesterone. Monitor depth of anesthesia closely.
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
ETHRANE (enflurane) is a potent inhalation anesthetic. Its use is limited due to risk of seizures at high doses and potential for nephrotoxicity from fluoride ion release. Avoid in patients with history of seizures or renal impairment. Rapid induction and recovery; use with caution in hypotensive patients due to myocardial depression. Malignant hyperthermia trigger.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
You will receive this anesthesia medication only in a hospital setting under expert supervision.,Possible side effects include nausea, vomiting, shivering, and confusion after waking up.,Tell your doctor if you have a history of seizures, kidney problems, or muscle disorders.,Avoid driving or operating machinery for at least 24 hours after anesthesia.,Do not eat or drink for the time specified by your healthcare team before surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUPRENZA vs ETHRANE, answered by our medical review team.
SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. ETHRANE is a General Anesthetic that works by Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUPRENZA and ETHRANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. The standard adult dose of ETHRANE is: 1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUPRENZA and ETHRANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. ETHRANE is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.